175 related articles for article (PubMed ID: 18851872)
1. XRCC1 Arginine194Tryptophan and GGH-401Cytosine/Thymine polymorphisms are associated with response to platinum-based neoadjuvant chemotherapy in cervical cancer.
Kim K; Kang SB; Chung HH; Kim JW; Park NH; Song YS
Gynecol Oncol; 2008 Dec; 111(3):509-15. PubMed ID: 18851872
[TBL] [Abstract][Full Text] [Related]
2. XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer.
Chung HH; Kim MK; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Gynecol Oncol; 2006 Dec; 103(3):1031-7. PubMed ID: 16875718
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer.
Sugiyama T; Nishida T; Hasuo Y; Fujiyoshi K; Yakushiji M
Gynecol Oncol; 1998 May; 69(2):130-6. PubMed ID: 9600820
[TBL] [Abstract][Full Text] [Related]
4. CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Costa S; Terzano P; Bovicelli A; Martoni A; Angelelli B; Santini D; Ceccarelli C; Lipponen P; Erzén M; Syrjänen S; Syrjänen K
Gynecol Oncol; 2001 Jan; 80(1):67-73. PubMed ID: 11136572
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
Huang ZH; Hua D; Du X
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
[TBL] [Abstract][Full Text] [Related]
6. Treatment of stage IB2, IIA bulky cervical cancer: a single-institution experience of neoadjuvant chemotherapy followed by radical hysterectomy and primary radical hysterectomy.
Lee JY; Kim YH; Kim MJ; Kim K; Chung HH; Park NH; Song YS; Kang SB
Arch Gynecol Obstet; 2011 Aug; 284(2):477-82. PubMed ID: 20878172
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
[TBL] [Abstract][Full Text] [Related]
8. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-pi in the tumor cells of cervical carcinoma.
Konishi I; Nanbu K; Mandai M; Tsuruta Y; Kataoka N; Nagata Y; Mori T
Gynecol Oncol; 1998 Sep; 70(3):365-71. PubMed ID: 9790789
[TBL] [Abstract][Full Text] [Related]
9. Radical surgery after neoadjuvant intra-arterial chemotherapy in stage IIIb squamous cell carcinoma of the cervix.
Sugiyama T; Nishida T; Muraoka Y; Tokuda T; Kuromatsu H; Fujiyoshi K; Yakushiji M; Edamitu O; Haynbuchi N
Int Surg; 1999; 84(1):67-73. PubMed ID: 10421022
[TBL] [Abstract][Full Text] [Related]
10. The impact of GGH -401C>T polymorphism on cisplatin-based chemoradiotherapy response and survival in cervical cancer.
Silva IH; Nogueira-Silva C; Figueiredo T; Lombo L; Faustino I; Catarino R; Nogueira A; Pereira D; Medeiros R
Gene; 2013 Jan; 512(2):247-50. PubMed ID: 23107767
[TBL] [Abstract][Full Text] [Related]
11. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population.
Liu B; Wei J; Zou Z; Qian X; Nakamura T; Zhang W; Ding Y; Feng J; Yu L
Eur J Hum Genet; 2007 Oct; 15(10):1049-53. PubMed ID: 17593927
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage IB2 to IIB) cervical cancer: randomized study.
Chen H; Liang C; Zhang L; Huang S; Wu X
Gynecol Oncol; 2008 Sep; 110(3):308-15. PubMed ID: 18606439
[TBL] [Abstract][Full Text] [Related]
14. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic study in rectal cancer patients treated with preoperative chemoradiotherapy: polymorphisms in thymidylate synthase, epidermal growth factor receptor, GSTP1, and DNA repair genes.
Páez D; Salazar J; Paré L; Pertriz L; Targarona E; del Rio E; Barnadas A; Marcuello E; Baiget M
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1319-27. PubMed ID: 21570215
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
[TBL] [Abstract][Full Text] [Related]
17. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
[TBL] [Abstract][Full Text] [Related]
18. [Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer].
Gorchev G; Kornovski Ia
Akush Ginekol (Sofiia); 2003; 42(6):21-4. PubMed ID: 15067810
[TBL] [Abstract][Full Text] [Related]
19. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
Joshi MB; Shirota Y; Danenberg KD; Conlon DH; Salonga DS; Herndon JE; Danenberg PV; Harpole DH
Clin Cancer Res; 2005 Mar; 11(6):2215-21. PubMed ID: 15788669
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma.
Choi CH; Kim TJ; Lee JW; Kim BG; Lee JH; Bae DS
Gynecol Oncol; 2007 Jan; 104(1):64-9. PubMed ID: 16904170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
